The 2026 priority is linked survey-claims data to follow dementia care over time. For people with mild cognitive impairment, participation surveys should ask about awareness, proxy answers, visit burden and trial access. Mild cognitive impairment means memory or thinking changes beyond normal aging but not dementia. According to the National Institute on Aging, key linked resources include NHATS/NSOC, the NIA Data LINKAGE program, the LTC Data Cooperative and Gateway tools, although data siloes remain, as described in the 2026 summit report.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Hhs — Use this primary source to verify the official guidance.
- Read the official guidance from Usc — Use this primary source to verify the official guidance.
Table of Contents
- Why link surveys to Medicare records?
- Why do surveys miss dementia and MCI?
- Which participation questions matter most for MCI?
- What should readers do with these answers?
Why link surveys to Medicare records?
The Health and Retirement Study shows the model. It is a national panel given every two years with cognitive testing. According to the Assistant Secretary for Planning and Evaluation, it links to Medicare and Medicaid files, death records and Social Security records.
Linkage lets researchers compare what people report with what claims record. It also lets them follow function, care use and death over time. Siloed records hide those patterns and slow caregiving research.
Why do surveys miss dementia and MCI?
Many people with a Medicare dementia diagnosis do not report it themselves. According to Yale University researchers, about 67% answering for themselves said no doctor had ever told them they had dementia, compared with 23% underreporting for hypertension and 17% for arthritis, as reported in the Futurity summary. The gap is wider for early change.
According to USC researchers, fewer than 8% of expected mild cognitive impairment cases among 40 million Medicare beneficiaries were diagnosed, leaving about 7.4 million of 8 million predicted cases undiagnosed, as reported in the USC Today story. For MCI surveys, that means self-report alone will undercount cases. Questionnaires need a diagnosis-awareness item and a flag for proxy versus self-report.
Which participation questions matter most for MCI?
Willingness is high but follow-through is low. In one 2,056-adult survey cited by the Global Alzheimer's Platform Foundation, 59% expressed willingness while under 10% actually took part, as reported in the DOTmed report. For MCI, where symptoms are mild and trial visits can feel heavy, surveys should find the friction points.
- Have you been told you have MCI or dementia, by whom, and when?
- Who answered this survey, you alone, with help, or a proxy?
- Could you manage extra clinic visits, memory tests, scans or blood draws?
- Have you received clear trial information and contact help in your language?
What should readers do with these answers?
Use the answers to plan the next talk with the care team. Bring the completed survey, a drug list and one family member who knows daily function. Ask whether the diagnosis is in the medical record and whether a proxy note is needed. Then ask for practical trial details before saying yes.
Ask about visit count, travel, time, costs, biomarker tests and who to call with questions. People who want research can also ask the clinic for a social worker, navigator or Alzheimer's Association trial-match referral. The 2026 Cost of Dementia Project estimated 5.7 million Americans age 51 and older have dementia, at $818 billion in total costs. Medicare and Medicaid cover about $154 billion of medical and long-term-care costs, so better linked data directly affects family budgets and policy.
You Might Also Like
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What People With Mild Cognitive Impairment Should Know About the News
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: What People With Mild Cognitive Impairment Should Know About the News
- Young-Onset Dementia Cost Gaps Identified by NIA in 2026: What the Report Establishes and Leaves Unanswered for Spouses and Partners
